Fibroblast growth factor-21, energy balance and obesity
- PMID: 26415590
- DOI: 10.1016/j.mce.2015.09.018
Fibroblast growth factor-21, energy balance and obesity
Abstract
Fibroblast growth factor (FGF)-21 is an endocrine member of the FGF family with healthy effects on glucose and lipid metabolism. FGF21 reduces glycemia and lipidemia in rodent models of obesity and type 2 diabetes. In addition to its effects improving insulin sensitivity, FGF21 causes weight loss by increasing energy expenditure. Activation of the thermogenic activity of brown adipose tissue and promotion of the appearance of the so-called beige/brite type of brown adipocytes in white fat are considered the main mechanisms underlying the leaning effects of FGF21. Paradoxically, however, obesity in rodents and humans is characterized by high levels of FGF21 in the blood. Some degree of resistance to the actions of FGF21 has been proposed as part of the endocrine alterations in obesity. The resistance in adipose tissue from obese rodents and patients is likely attributable to abnormally low levels of the FGF co-receptor β-Klotho, required for FGF21 cellular action. However, native FGF21 and FGF21 derivatives retain their healthy metabolic and weight-loss effects when used as pharmacological agents to treat obese rodents and humans. FGF21 derivatives or molecules mimicking FGF21 action appear to be interesting candidates for the development of novel anti-obesity drugs designed to increase energy expenditure.
Keywords: Brown adipose tissue; Energy expenditure; FGF21; White adipose tissue.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Modulation of energy balance by fibroblast growth factor 21.Horm Mol Biol Clin Investig. 2016 Jun 20;30(1):/j/hmbci.2017.30.issue-1/hmbci-2016-0023/hmbci-2016-0023.xml. doi: 10.1515/hmbci-2016-0023. Horm Mol Biol Clin Investig. 2016. PMID: 27318658 Review.
-
Chronic high-sucrose diet increases fibroblast growth factor 21 production and energy expenditure in mice.J Nutr Biochem. 2017 Nov;49:71-79. doi: 10.1016/j.jnutbio.2017.07.010. Epub 2017 Jul 25. J Nutr Biochem. 2017. PMID: 28886439
-
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.Endocrinology. 2012 Jan;153(1):69-80. doi: 10.1210/en.2010-1262. Epub 2011 Nov 8. Endocrinology. 2012. PMID: 22067317
-
FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.Mol Metab. 2017 Nov;6(11):1454-1467. doi: 10.1016/j.molmet.2017.09.003. Epub 2017 Sep 18. Mol Metab. 2017. PMID: 29107292 Free PMC article.
-
Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.Eur J Endocrinol. 2012 Sep;167(3):301-9. doi: 10.1530/EJE-12-0357. Epub 2012 Jun 27. Eur J Endocrinol. 2012. PMID: 22740503 Review.
Cited by
-
Thermogenic Fat: Development, Physiological Function, and Therapeutic Potential.Int J Mol Sci. 2021 May 31;22(11):5906. doi: 10.3390/ijms22115906. Int J Mol Sci. 2021. PMID: 34072788 Free PMC article. Review.
-
Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.Oxid Med Cell Longev. 2022 May 29;2022:5042762. doi: 10.1155/2022/5042762. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35677107 Free PMC article. Review.
-
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.Curr Obes Rep. 2018 Jun;7(2):147-161. doi: 10.1007/s13679-018-0300-4. Curr Obes Rep. 2018. PMID: 29504049 Review.
-
The Role of Exerkines in Obesity-Induced Disruption of Mitochondrial Homeostasis in Thermogenic Fat.Metabolites. 2024 May 17;14(5):287. doi: 10.3390/metabo14050287. Metabolites. 2024. PMID: 38786764 Free PMC article. Review.
-
Biocompatible Macroion/Growth Factor Assemblies for Medical Applications.Biomolecules. 2023 Mar 28;13(4):609. doi: 10.3390/biom13040609. Biomolecules. 2023. PMID: 37189357 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical